MAIN CONTENT
A settlement without published terms
Chief Judge Michael Shea of the US District Court in Hartford put the states' action on hold on Monday after being notified of an agreement in principle. That status signals substantial progress toward resolution, but it does not provide the public with a payment amount, compliance commitments or a timetable for formal completion. Teva and Connecticut Attorney General William Tong's office had not immediately commented when Reuters reported the development.
The legal distinction matters. A negotiated settlement is not equivalent to a court ruling that every allegation has been proved. Nor can observers infer from undisclosed terms how money, if any, would be distributed to public purchasers or consumers. Questions about related claims involving other companies must be considered separately rather than assumed to have been settled along with Teva's dispute.
How the states described the alleged scheme
The plaintiffs accused drug companies of coordinating market shares and increases in the prices of generic medicines instead of competing independently. According to the states' allegations, the conduct began around 2012 and accelerated in 2013 and 2014.
















